Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NewAmsterdam Pharma Company ( (NAMS) ) just unveiled an update.
NewAmsterdam Pharma Company has entered into an underwriting agreement for a public offering of its ordinary shares and pre-funded warrants, raising approximately $452.6 million. The underwriters have exercised their option to purchase additional shares, with the offering expected to enhance the company’s financial position as it pursues its clinical trials and commercialization efforts for its LDL-lowering therapies.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients with cardiovascular disease and elevated LDL cholesterol. The company aims to address unmet needs for safe and effective LDL-lowering therapies, particularly for patients who do not tolerate existing treatments well.
YTD Price Performance: 124.62%
Average Trading Volume: 654,633
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.32B
For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.
